Gubra

"Management strikes a confident, milestone-driven tone anchored by the landmark AbbVie deal and strong Phase 1 clinical data, while appropriately acknowledging the CRO revenue softness. For a biotech/pharma company, this tone is typical to slightly more positive than average — the clinical data language ('exceeded our expectations', 'remarkable weight loss', 'best-in-class') is notably assertive for a Phase 1 readout."